LXEO
Lexeo Therapeutics Inc
NASDAQ · Biotechnology
$7.16
+0.27 (+3.92%)
Open$7.05
Previous Close$6.89
Day High$7.55
Day Low$6.88
52W High$10.99
52W Low$1.45
Volume—
Avg Volume874.5K
Market Cap522.59M
P/E Ratio—
EPS$-2.70
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+549.0% upside
Current
$7.16
$7.16
Target
$46.47
$46.47
$27.16
$46.47 avg
$57.70
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 110.56M | 98.68M | 97.87M |
| Net Income | 17.37M | 14.67M | 15.60M |
| Profit Margin | 15.7% | 14.9% | 15.9% |
| EBITDA | 19.93M | 19.03M | 18.02M |
| Free Cash Flow | 11.85M | 8.63M | 11.57M |
| Rev Growth | +16.0% | -2.8% | +7.5% |
| Debt/Equity | 0.49 | 0.46 | 0.54 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |